This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Serine/threonine-protein kinase PAK 3.
Activation by the binding of active CDC42 and RAC1 leads to a conformational change and a subsequent autophosphorylation on several serine and/or threonine residues. Phosphorylates MAPK4 and MAPK6 and activates the downstream target MAPKAPK5, a regulator of F-actin polymerization and cell migration.
Human | |
---|---|
Gene Name: | PAK3 |
Uniprot: | O75914 |
Entrez: | 5063 |
Belongs to: |
---|
protein kinase superfamily |
beta-PAK; bPAK; CDKN1A; EC 2.7.11; EC 2.7.11.1; hPAK3; mental retardation, X-linked 47; MRX30; MRX47; oligophrenin-3; OPHN3; p21 (CDKN1A)-activated kinase 3; p21 protein (Cdc42/Rac)-activated kinase 3; p21-activated kinase 3; PAK3; PAK-3; PAK3beta; serine/threonine-protein kinase PAK 3
Mass (kDA):
62.31 kDA
Human | |
---|---|
Location: | Xq23 |
Sequence: | X; NC_000023.11 (110944241..111227361) |
Restricted to the nervous system. Highly expressed in postmitotic neurons of the developing and postnatal cerebral cortex and hippocampus.
Cytoplasm.
PAK3 is a protein that regulates Smad4-dependent tumorigenesis, progression, and metastasis in lung cancer. This protein can be treated with high-affinity primary antibodies. Boster has partnered globally with scientists to provide these tools. Boster scientists are also able to submit results for applications or special samples to earn product credit. This product is accessible to all scientists from medical researchers to lab researchers.
Lung cancer has a high rate of mutations in SMAD4. It is not known what the exact mechanism behind SMAD4's loss of function is. A mouse model with both Smad4fl/fl and conditional p53fl/fl mutations was used to study the role of Smad4 for lung cancer. This model shows significantly increased metastasis than wild-type mice. This mouse model also increases PAK3 expression, which mediates the signal transduction pathway involved in the metastatic reaction. PAK3 can be upregulated by Smad4dependent transcription.
This study found that Smad4 is expressed lower in lung cancer than in normal lung tissue. Smad4 expression levels were found to correlate with lymphatic metastasis or stage of the cancer. Further research is needed to determine how Smad4 contributes tumorigenesis. While we are not able to determine the exact mechanism of Smad4, researchers and doctors can use the results.
Most recently, Smad4 LOF has been implicated in lung cancer progression and metastasis. These mice were created using nasal delivery of Cre Recombinase. After a long latent stage, Smad4 deficient mice developed lung tumours. The mice were resistant and showed higher tumor growth.
In this study, the Smad4 marker in lung cancer was assessed by ELISA. After pre-incubation with primary antibody, the Smad4 antibodies were applied to tissue sections. The samples were then incubated with primary antibodies overnight in a humidified chamber. After incubation, sections were stained using DAB.
There are many benefits to using the PAK3 marker. The marker is useful for identifying patients with intellectual impairment. The PAK3 gene is required for glucose homeostasis. It is essential for normal metabolic rates even under difficult conditions. To detect any potential disease, it is essential to understand its function. The PAK3 Gene is derived by Neurog3, a novel neurohormone-specific gene.
Steve Boster's death was announced in 2022. He died June 26, 20,22. He was born in Joliet, IL. Boster was an entrepreneur and manager of retail sales for over 25 years. He was also a Concordia Hall member in Staunton, Virginia. His 2 daughters, Natosha Peck and Crystal Boster, survive him. He has 6 grandchildren. His four brothers Jack Boster, Sandra Blanton, and Sandra Blanton are his survivors. He is also survived by his son Jonathan and his grandson Cory.
The company was started in 1993. By the late 90s, it had grown to be the largest catalog anti-body company in China. Steve's background and work ethic earned the nickname "he the converts science to the lavatory." He grew his business and developed hundreds of primary antibodies. In the late 90s, Steven Boster developed his own proprietary ELISA platform, PicoKine(tm), which delivers high-sensitivity ELISA kits.
The PAK3 marker is key for identifying a wide range proteins found in cells and tissues. Flow cytometry is a popular technique in research, diagnostics, and drug discovery, with many potential applications in the medical and scientific fields. Whether you're looking for a monoclonal antibody or a polyclonal antibody, Boster Bio high-affinity primary antibodies using the PAK3 marker will help you identify antigens with a high level of specificity.
PAK3 is a versatile marker that is highly specific and has been used to identify antibodies for more than a decade. Boster Bio has simplified the production of high-affinity antibodies against specific antigens by using PAK3. This allows scientists to create antibodies that target specific epitopes. These antibodies can also be characterized and measured.
High-affinity primaries antibodies based upon the PAK3 marker are sensitive and highly specific to human cell. They can be used to dual label specimens, which allows researchers more information and context-specific answers. This is the reason that PAK3 was chosen. This antibody has a high affinity and is therefore highly specific. This makes it an invaluable tool in research.
Boster Bio's PAK3 Cell based ELISA kits provides a high-throughput, convenient method for measuring PAK3 protein levels in cultured cells. It can also be used to monitor the effects of activators or treatments on PAK3 levels. This kit is not available for individual purchase. This kit is limited to BosterBio products. This kit allows researchers detect changes in PAK3 status in living cells.
This Cell-based PAK3ELISA is highly specific in detecting PAK3 expression in a variety cell types. It detects the PAK3 protein in h2299-transfected SPK cells. This kit is ideal to study PAK3 expression in cancer cells. It also works well for assessing the effects of various RNAi drugs on PAK3 expression.
The Smad4 protein regulates PAK3, which is a crucial pathway in lung cancer. Researchers have a new technology that allows them to monitor lung cancer prognosis. It also provides insight on the process of tumorigenesis progression and metastasis. This new technology is an important tool for researchers in cancer research because of its reliability and speed.
PMID: 9731525 by Allen K.M., et al. PAK3 mutation in nonsyndromic X-linked mental retardation.
PMID: 12777533 by Kitano T., et al. Gene diversity patterns at 10 X-chromosomal loci in humans and chimpanzees.